Status:
UNKNOWN
Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
PRIMARY FOCUS:PATIENT THAT TAKE CLOPIDOGREL
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to check correlation between CYP2C19 genotype level of clopidogrel metabolite in plasma and platelet inhibition status.
Detailed Description
THE FIRST PHASE OF THE RESEARCH WILL INVOLVE PATIENTS RECRUITMENT AND INFORMED CONSENT FOR GENETIC TESTING.THE MAJORITY OF PATIENTS WILL BE RECRUITED FROM EMERGENCY DEPARTMENT. EVERY PATIENT WILL BE A...
Eligibility Criteria
Inclusion
- \> 18 OLD PATIENTS
- THAT TAKE CLOPIDOGREL MORE THAN 1 WEEK
Exclusion
- PREGNANCY
- CHRONIC LIVER DISEASES
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01210248
Start Date
September 1 2010
Last Update
September 28 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assaf Harofeh Medical Center
Zeriffin, Israel, Israel